Indications And Dose
HIV infection in patients with plasma HIV-1 RNA concentration of 100 000 copies/mL or less (specialist use only) ▶BY MOUTH ▶Adult: 1 tablet once daily
PDF page 709
Loading InternPractice…
Drug reference
HIV infection in patients with plasma HIV-1 RNA concentration of 100 000 copies/mL or less (specialist use only) ▶BY MOUTH ▶Adult: 1 tablet once daily
PDF page 709
Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (October 2016) that emtricitabine with rilpivirine and tenofovir alafenamide (Odefsey ®) is accepted for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV-1), without known mutations associated with resistance to the non-nucleoside reverse Infection transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV-1 RNA of 100 000 copies/mL or less. All Wales Medicines Strategy Group (AWMSG) decisions The All Wales Medicines Strategy Group has advised (November 2016) that emtricitabine with rilpivirine and tenofovir alafenamide (Odefsey ®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1, without known mutations associated with resistance to the non- nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV-1 RNA of 100 000 copies/mL or less.
PDF page 710
→Appendix 1: rilpivirine. tenofovir alafenamide
PDF page 709
▶Common or very common Appetite decreased. depression. diarrhoea. dizziness. drowsiness. dry mouth. fatigue. flatulence. gastrointestinal discomfort. headache. nausea . skin reactions. sleep disorders. vomiting ▶Uncommon Anaemia. angioedema. arthralgia. immune reconstitution inflammatory syndrome ▶Frequency not known Conjunctivitis. drug reaction with eosinophilia and systemic symptoms (DRESS). eosinophilia. fever. osteonecrosis. QT interval prolongation. weight increased SIDE-EFFECTS, FURTHER INFORMATION Systemic symptoms reported with severe skin reactions include fever, blisters, conjunctivitis, angioedema, elevated liver function tests, and eosinophilia.
PDF page 709
Manufacturer advises caution in moderate impairment (increased risk of hepatic side- effects); avoid in severe impairment (no information available).
PDF page 709
Manufacturer advises avoid if creatinine clearance less than 30 mL/minute—no information available.
PDF page 709
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 3, 21 ▶Odefsey (Gilead Sciences International Ltd) A Rilpivirine (as Rilpivirine hydrochloride) 25 mg,Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 25 mg, Emtricitabine 200 mg Odefsey 200mg/25mg/25mg tablets | 30 tablet P £525.95
PDF page 710
Vomiting Manufacturer advises if vomiting occurs within 4 hours of taking a dose, a replacement dose should be taken. Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.
PDF page 709
1 tablet once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 709